[144] SentinelOne, Inc. SEC Filing

Rhea-AI Filing Summary

Clover Health Investments, Corp. (CLOV) has filed a Form 144 indicating a proposed sale of insider shares.

• Shares to be sold: 2,012 common shares
• Estimated market value: $5,150.72
• Broker: Morgan Stanley Smith Barney LLC, New York
• Planned execution date: 07/07/2025 on NASDAQ
• Total shares outstanding: 416,541,578 (sale equals ~0.0005% of float)

The filing also lists recent 10b5-1 sales by the same insider, Jamie Reynoso, totaling 40,239 shares for gross proceeds of $109,504.30 across two transactions on 06/17/2025 and 07/03/2025.

Because the proposed sale is immaterial relative to the company’s share count, the market impact is expected to be minor; however, continual insider selling can be perceived negatively by some investors.

Positive

• Volume immaterial: 2,012 shares represent just 0.0005% of outstanding stock, implying negligible dilution.

Negative

• Continued insider selling: Insider has already sold 40,239 shares this quarter, which may be perceived as bearish sentiment.

Insights

Financial Analyst

TL;DR: Small Form 144 sale; negligible dilution but signals ongoing insider selling.

The notice covers a sale of just 2,012 shares (<$6k), representing a fraction of CLOV’s 416.5 million shares. While quantitatively insignificant, it follows two earlier 10b5-1 sales totaling 40k shares this quarter, which could concern investors tracking sentiment. No financial metrics are provided; thus, valuation impact is minimal. Overall, the filing is routine and not likely to affect price absent larger trends.

Corporate Governance Specialist

TL;DR: Routine compliance filing; shows transparent 10b5-1 trading plan.

The insider certifies lack of undisclosed adverse information and references a 10b5-1 plan, satisfying regulatory best practices. Volume sold is trivial, reinforcing that this is standard liquidity management rather than a strategic exit. Governance risk is low, but cumulative insider sales may warrant monitoring if pace accelerates.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Common	Raymond James & Associates 880 Carillon Parkway St. Petersburg FL 33716	1117200	20109600.00	318339537	07/07/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Common	05/31/2019	Stock Conversion before IPO	SentinelOne, Inc.			12902253	05/31/2019	Wired to portfolio company.

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Clover Health (CLOV) shares are being sold under this Form 144?

2,012 common shares are slated for sale.

What is the approximate value of the proposed CLOV share sale?

The aggregate market value is $5,150.72.

When is the planned sale date for the CLOV shares?

The insider plans to sell on 07/07/2025.

Which broker is handling the CLOV Form 144 transaction?

Morgan Stanley Smith Barney LLC, New York.

How many CLOV shares are outstanding according to the filing?

The company reports 416,541,578 shares outstanding.

What recent insider sales of CLOV stock were disclosed?

Sales of 19,789 shares on 07/03/2025 and 20,450 shares on 06/17/2025, totaling 40,239 shares.